Jim Cramer's Mad Money Stock Recap May 14th
Winner CEO: Fred Hassan, Schering-Plough (NYSE: SGP)
Cramer said he is dedicating a weekly series to "transformational CEOs" who have "managed to turn around dead franchises into living, thriving ones." In 2003, Fred Hassan took the helm of SGP, and replaced Richard Kogan, who left the company with $1 billion in debt and was "the worst of the worst" among CEOs. Since then, the stock has doubled and Fred Hassan has led the company through ten straight quarters of double-digit sales growth. Currently, SGP has a pipeline full of new drugs and Cramer believes the stock will go higher.
Not a Chicken on Earnings: Buffalo Wild Wings (NasdaqGS: BWLD)
One of the top conference calls this season was BWLD, and Cramer believes its "excellent" CEO Sally Smith has the company under control. Same store sales were up 8.7%, and earnings per share increased 58% year over year. In addition, the cost of the BWLD's food is not being affected by rising corn prices. Cramer feels the company will underpromise and overdeliver, is a regional-to-national story and is a long way from its saturation point.
A Healthy Choice: Chipotle Mexican Grill (NYSE: CMG)
Another winning conference call was that of CMG, whose CEO, Steve Ells, expressed confidence that CMG is outperforming its competitors. After the call, the stock reached a new high of $83. Steve Ells commented CMG is not wasting money and resources on revamping its menu or coming up with unusual marketing techniques or themes, but is featuring "green" food from naturally raised beef and cows which have not been treated with synthetic growth hormones. The company saw a 46.2% increase in earnings per share, and raised its guidance. Cramer is bullish on CMG.
CEO Interview: Medicis Pharmaceutical (NYSE: MRX) Jonah Shacknai with Allergan (NYSE: AGN)
Jonah Shacknai is skeptical that investment houses and analysts have MRX's numbers right, since the company does not publish numbers. He adds MRX raised its guidance. Shacknai discussed Solodyn, a drug which has been successful and has room to grow. Another drug, Restylane, is safe and effective for treating wrinkles, has done well overseas and should perform well in the U.S, he said. Cramer said he likes MRX along with AGN.
Cramer said he is dedicating a weekly series to "transformational CEOs" who have "managed to turn around dead franchises into living, thriving ones." In 2003, Fred Hassan took the helm of SGP, and replaced Richard Kogan, who left the company with $1 billion in debt and was "the worst of the worst" among CEOs. Since then, the stock has doubled and Fred Hassan has led the company through ten straight quarters of double-digit sales growth. Currently, SGP has a pipeline full of new drugs and Cramer believes the stock will go higher.
Not a Chicken on Earnings: Buffalo Wild Wings (NasdaqGS: BWLD)
One of the top conference calls this season was BWLD, and Cramer believes its "excellent" CEO Sally Smith has the company under control. Same store sales were up 8.7%, and earnings per share increased 58% year over year. In addition, the cost of the BWLD's food is not being affected by rising corn prices. Cramer feels the company will underpromise and overdeliver, is a regional-to-national story and is a long way from its saturation point.
A Healthy Choice: Chipotle Mexican Grill (NYSE: CMG)
Another winning conference call was that of CMG, whose CEO, Steve Ells, expressed confidence that CMG is outperforming its competitors. After the call, the stock reached a new high of $83. Steve Ells commented CMG is not wasting money and resources on revamping its menu or coming up with unusual marketing techniques or themes, but is featuring "green" food from naturally raised beef and cows which have not been treated with synthetic growth hormones. The company saw a 46.2% increase in earnings per share, and raised its guidance. Cramer is bullish on CMG.
CEO Interview: Medicis Pharmaceutical (NYSE: MRX) Jonah Shacknai with Allergan (NYSE: AGN)
Jonah Shacknai is skeptical that investment houses and analysts have MRX's numbers right, since the company does not publish numbers. He adds MRX raised its guidance. Shacknai discussed Solodyn, a drug which has been successful and has room to grow. Another drug, Restylane, is safe and effective for treating wrinkles, has done well overseas and should perform well in the U.S, he said. Cramer said he likes MRX along with AGN.
posted by Stock Administrator @ 9:54 AM
0 Comments:
Post a Comment
<< Home